• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·EVERESTO.BO
Share

Everest Organics Limited Stocks

₹ 250.1Last Updated 19.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 23.91M

₹ 250.1
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Everest Organics Limited is a pharmaceutical enterprise specializing in the production of bulk drugs. Its product line encompasses compounds such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, and Benzimadizole. Additionally, the company manufactures and exports active pharmaceutical ingredients (APIs) and their intermediates from its facilities in India, supplying these to formulation companies worldwide. The firm was founded on February 19, 1993, and its headquarters are located in Hyderabad, India.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.10.2026 21:10

Shares of Ray-Ban had their best day since 2008. Should you buy them?

21.10.2026 20:20

The Old World on New Chips: How Nvidia Is Driving the Industrial Revolution in Europe

21.10.2026 20:13

Getty Images has filed for bankruptcy. It will become privately owned.

21.10.2026 19:00

SpaceX's strong results boosted U.S. stocks. Is the worst behind us?

21.10.2026 18:30

"The Music's Still Playing": What Wall Street Recommends Doing with Meta Shares Ahead of the Earnings Report

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026